Asploro Journal of Biomedical and Clinical Case Reports ISSN: 2582-0370 Article Type: Case Report DOI:…Keep reading
About Asploro Journal of Biomedical and Clinical Case Reports [ASJBCCR]
Asploro Journal of Biomedical and Clinical Case Reports is an open access, peer-reviewed journal which mainly aims to directly improve global health outcomes and share clinical knowledge using case reports to convey important best practice messages. Each case report published in this journal adds valuable new information to medical knowledge.
Case Reports are the first piece of research writing in the health field and represent the most basic type of study design. They make a contribution to health knowledge and have educational value or highlight the need for a change in clinical practice or diagnostic/prognostic approaches. If your submission has an important clinical message we would like to read it!
ASJBCCR welcomes original case reports that expands the field of general medical knowledge, clinical images, procedural videos, original research relating to case reports, and short communications from all areas of Medicine, Nursing, Dentistry, and Veterinary Science. Case reports can span the full spectrum of health sciences in the broadest sense, including biochemistry, microbiology, developmental biology, cell biology, genetics, immunology, molecular biology, structural biology, translational medicine, protein science, clinical epigenetics, clinical trials, clinical pharmacology, physiology, neuroscience, etc.,
Submit manuscript as an e-mail attachment to the Editorial Office at email@example.com
Why Publish With Us
- All the published articles are open access which means it’s free to access from anywhere in the world.
- We offer fast publication while providing rigorous peer review to maintain the integrity of information.
- Each article will be published under a Creative Commons license and authors are the copyright holder.
- We are committed to the highest standards of peer review.
- We’re proud of the impact and influence this journal have – from citations to social media shares.
- We’re committed to promoting your work as widely as we can and providing as much visibility and exposure for your article as possible.
Most Recent Articles
Case Report | Asp Biomed Clin Case Rep. 2022 Jun 27;5(2):68-72 | DOI: 10.36502/2022/ASJBCCR.6266
Author(s): Ashwin Sidhu*, Harrison Chu
A significant portion of all invasive fungal infections in solid organ transplants are due to cryptococcus. It can be a debilitating infection and affects the quality of life in transplant patients. We report a case of a 57-year-old male patient with recent kidney transplant, who presented with cryptococcal meningitis, after exposure to birds during a trip to Mexico 1 week ago. In addition to a two-day history of generalized weakness, dizziness, intermittent fever, and lightheadedness, the patient presented with on and off headaches, increased sinus pressure, neck stiffness, clogged ear sensation, confusion, and night sweats. The patient was initially treated empirically with fluconazole. Lumber punctuation showed elevated opening pressure, increased WBC, with neutrophil predominance. Cryptococcal antigen tests were positive in both serum and cerebrospinal fluid sources. After confirmation from CSF analysis, he was administered liposomal amphotericin B and flucytosine. Patient’s symptoms rapidly improved. Due to his immunocompromised state, the patient will require lifelong fluconazole maintenance therapy. Even though kidney transplant recipients have a positive outcome in terms of longevity, they are at increased risk of post-transplant infection, such as zoonotic infections. Therefore, in any recent kidney transplant patient with meningitis symptoms, cryptococcal meningitis should always be considered. We report the appropriate criteria, procedures, and tests that allow for a cryptococcal meningitis diagnosis in immunocompromised patients.
Case Report | Asp Biomed Clin Case Rep. 2022 May 21;5(2):63-67 | DOI: 10.36502/2022/ASJBCCR.6265
Author(s): Yoshinobu KATO, Hiroshi BANDO*, Yoshikane KATO, Katsunori OGURA, Hisako YAMASHITA
The patient is an 83-year-old male, who smoked 20-40 cigarettes daily during 20-75 years and quit after that. In March 2021, he revealed normal chest X-P and was explained to take chest computed tomography (CT) next year. In April 2022, chest X-P was unremarkable, but CT showed a small solid abnormal shadow in the upper left lung region nearby aortic arch and abdominal aortic aneurysm (AAA) in the upper abdomen. Almost lung cancer cases are found in current smokers or ex-smokers. Using CT, lung cancer screening shows a 20-26% decrease in cancer death. Consequently, Low-Dose CT (LDCT) for smokers would be recommended.
Original Article | Asp Biomed Clin Case Rep. 2022 May 02;5(2):59-62 | DOI: 10.36502/2022/ASJBCCR.6264
Assessment of Quality of Life and Respiratory Functional Capacity in Individuals Recovered from COVID-19
Author(s): Cristianne Confessor Castilho Lopes*, Daniela dos Santos, Gizele Locatelli, Tulio Gamio Dias, Ana Paula de Oliveira Barbosa, Eduardo Barbosa Lopes, Lucas Castilho Lopes, Vanessa da Silva Barros, Paulo Sergio Silva, Fábio Herget Pitanga, Liamara Basso Dala Costa, Youssef Elias Ammar
Covid-19 is an infectious disease that causes inflammation in the respiratory system, is contagious and spreads rapidly. The sequelae caused after infection and treatment of Covid-19 are not fully known. The study aims to evaluate the quality of life and respiratory capacity of individuals who have been contaminated by the Covid-19 virus. This study is characterized as descriptive, with a cross-sectional design and a quantitative-qualitative approach. The sample consisted of 54 participants, of both sexes, diagnosed with Covid-19, who were hospitalized or not. Data collection was carried out through a mixed online questionnaire, developed on the Google Docs® platform. The results pointed to a worse quality of life in the domains Limitations due to physical aspects, Pain, Vitality, Limitations due to emotional aspects and a better quality of life for the domains Functional Capacity, General State of Health and Mental Health. And a worse quality of life assessed from the respiratory disease. It is concluded that the quality of life was affected and impaired after being affected by Covid-19 and that Physiotherapy helps to improve the sequelae and resumption of day-to-day activities, generating a good recovery.
Original Article | Asp Biomed Clin Case Rep. 2022 Apr 04;5(1):51-58 | DOI: 10.36502/2022/ASJBCCR.6263
Efficient Weight Loss and Type II Diabetes Control in Overweight and Obese Patients Consuming the Probiotic Bacillus Subtilis DG101: A Randomized Double-Blind Placebo-Controlled Study
Author(s): Facundo Rodríguez Ayala, Néstor Cardinali, Roberto Grau*
Objective: Obesity is a worldwide endemic disease with limited options for treatment. Studies have indicated that the probiotic Bacillus subtilis can reduce weight gain and serum lipid levels in animal models. However, there are no publications showing positive results on the anti-obesity effect in humans. Here, we investigated the anti-obesity effect of the probiotic B. subtilis DG101 (i.e., reductions in weight, corporal fat content, and BMI) on overweight/obese subjects and the management of their HbA1c and insulin values.
Design: A randomized, double-blinded, placebo-controlled study.
Methods: A total of 294 subjects were divided into two groups according to sex. The subjects were randomly assigned to receive a daily dose of the probiotic B. subtilis DG101 or pure water (placebo) in all cases combined with a low-caloric/low-fat diet for 12 weeks. Weight, fat percentage, and BMI were measured, as well as HbA1c and insulin levels before and after the intervention.
Results: The probiotic B. subtilis DG101 significantly reduced weight, fat percentage, and BMI after 12 weeks of the intervention compared to the placebo (p<0.05). There was a significant reduction of HbA1c and insulin levels between the groups (p<0.05). Conclusions: Ingestion of the probiotic B. subtilis DG101 as an adjuvant in the anti-obesity therapy compared with placebo for 12 weeks significantly reduce obesity related parameters. Our finding of lower HbA1c and insulin levels in pre-diabetic and diabetic patients during ingestion of the probiotic B. subtilis DG101 validated one of our previous reports.
Case Report | Asp Biomed Clin Case Rep. 2022 Apr 02;5(1):46-50 | DOI: 10.36502/2022/ASJBCCR.6262
Author(s): Jasminder Malhi*, Navneet Sandhu, Xavier Salinas
ACE-inhibitor induced angioedema is a rare, potentially life-threatening phenomenon with unpredictable symptoms. With advanced angioedema, orotracheal intubation may not be possible necessitating nasotracheal intubation or cricothyroidotomy. This case describes a 76-year-old male with a history of hypertension controlled with lisinopril-hydrochlorothiazide who developed sudden-onset angioedema. Additionally, this case was complicated by the patient’s anticoagulation after recent abdominal aortic aneurysm repair. The patient’s acute respiratory distress was managed with nasotracheal intubation because of severe edema of the oral cavity including at the base of the tongue without improvement with epinephrine, a corticosteroid, or an antihistamine. He was extubated the following day, but mild edema of the oral cavity and left side of face persisted at discharge 4 days after presentation. When presenting to the emergency room with angioedema mediated via ACE-inhibitor use, time is of the essence to avoid cardiopulmonary arrest secondary to hypoxemia. Rapid identification and management of this condition is key to improve outcomes. After acute management, patients should be advised to avoid all ACE-inhibitors in the future.